Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.

Ying J, Wang Z, Wang J, Xia M

Open source

DOI
10.2147/cmar.s607440
Published
2026
Container
Cancer management and research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/cmar.s607440,
  title = {Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.},
  author = {Ying J and Wang Z and Wang J and Xia M},
  year = {2026},
  journal = {Cancer management and research},
  doi = {10.2147/cmar.s607440},
  url = {https://doi.org/10.2147/cmar.s607440}
}

RIS

TY  - JOUR
TI  - Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.
AU  - Ying J
AU  - Wang Z
AU  - Wang J
AU  - Xia M
PY  - 2026
JO  - Cancer management and research
DO  - 10.2147/cmar.s607440
UR  - https://doi.org/10.2147/cmar.s607440
ER  - 

APA

J, Y., Z, W., J, W., & M, X. (2026). Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.. Cancer management and research. https://doi.org/10.2147/cmar.s607440

Source records